STOCK TITAN

Gyre Therapeutics (GYRE) Stock News, Nov-Dec 2023

GYRE NASDAQ

Gyre Therapeutics, Inc. reports commercial-stage biopharmaceutical developments tied to organ fibrosis, inflammatory diseases and cancer-focused pipeline expansion. The company generates revenue through Gyre Pharmaceuticals in China, including ETUARY® (pirfenidone) and other commercial products, while advancing Hydronidone (F351) for chronic hepatitis B-associated liver fibrosis and MASH-associated liver fibrosis.

Recurring updates include quarterly results, revenue guidance, China NMPA and CDE interactions, NDA disclosures for F351, pirfenidone indication-expansion studies in lung fibrosis, and integration of Cullgen’s targeted protein degrader and degrader antibody conjugate candidates after the completed acquisition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.91%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
none

FAQ

What is the current stock price of Gyre Therapeutics (GYRE)?

Gyre Therapeutics (GYRE) last closed at $4.21.

What is the market cap of Gyre Therapeutics (GYRE)?

The market cap of Gyre Therapeutics (GYRE) is approximately $460.8M.